• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Which New Combination for Metastatic Renal Cell Cancer?

0
  • by Peter Goodwin
  • in AJO · Audio · Oncology
  • — 12 Nov, 2018
Which New Combination for Metastatic Renal Cell Cancer?
Which Molecular Drug Combinations for Renal Cancer?

MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the European Society for Medical Oncology (ESMO). Progress was reported with purely immunological approaches—using two different programmed death ligand 1 (PD-L1) targeted immunotherapies together—and also with therapies combining immunotherapy with tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor (VEGF).

Although such combinations had improved progression free survival (PFS) and even promised prolongation of overall survival (OS) the lack of comparisons between them left clinicians with little guidance—other than toxicity profiles—upon which to individualize treatment for their patients.

No biomarkers

“Unfortunately we don’t have good biomarkers that would help us selecting patients who would benefit either from immunotherapy alone, VEGF targeting agents alone, or the combination. So we have to look at the safety profiles of the combinations that we have right now—either the combinations with immunotherapies (alone) or the combination of a VEGF targeting agent and an anti PD-L1 drug—and see what would be the best for the patient that you have in front of you,” the Audio Journal of Oncology heard from John B.A.G. Haanen MD PhD, Chief Scientific Officer Immunotherapy and Consultant Medical Oncologist in the Division of Medical Oncology and Immunotherapy at the Netherlands Cancer Institute in Amsterdam.

 

Share

Tags: molecular drugs for renal cancerrenal cell cancertargeted combinations for kidney cancer

You may also like...

  • Daniel W. Lee Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia 6 Aug, 2013
  • George Demetri Blood test reliably detects cancer mutations in gastrointestinal stromal tumour 24 Apr, 2013
  • Audio Journal of Oncology in Advance – November 15th, 2006 Audio Journal of Oncology in Advance – November 15th, 2006 15 Nov, 2006

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Two Drug Combination Doubled Kidney Cancer Progression Free Survival
  • Next story Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”
  • News

    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014
  • Related interviews

    • Women With DCIS Live Longer Than General Population
    • Nuclear War: The Facts Today
    • Ibrutinib: New Frontline Standard for Chronic…
    • Second-Generation ALK Inhibitor = Longer PFS in ALK+…
    • Lung Cancer—First-Line Checkpoint Inhibitor…
  • Home
  • Oncology
  • AJO
  • Which New Combination for Metastatic Renal Cell Cancer?

© COPYRIGHT 2013 AUDIOMEDICA.COM.